MannKind Corporation (MNKD) news stock charts
MannKind Corporation (MNKD) Investment Summary:
Unless the context requires otherwise, the words “MannKind,” “we,” “company,” “us” and “our” refer to MannKind Corporation and its subsidiary. OVERVIEW MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. This dry powder therapy consists of our proprietary Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using our proprietary MedTone inhaler. We believe that the performance characteristics, unique kinetics, convenience and ease of use of our Technosphere Insulin System may have the potential to change the way diabetes is treated. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0000950124-08-001242.html#FIS_BUSINESS"www.mannkindcorp.com
Founded in 1991
MANNKIND CORP (MNKD:NASDAQ)
LAST $7.50 USD
CHANGE TODAY +0.01 0.13%
VOLUME 3.1M
As of 8:10 PM 03/18/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of MANNKIND CORP (MNKD)
|
OPEN
$7.52
|
PREVIOUS CLOSE
$7.49
|
|
|
DAY HIGH
$7.78
|
DAY LOW
$7.36
|
|
|
52 WEEK HIGH
09/22/09 - $12.30
|
52 WEEK LOW
03/20/09 - $3.20
|
|
|
MARKET CAP
850.2M
|
AVERAGE VOLUME 10 D
4.2M
|
|
|
EPS TTM
$-2.07
|
SHARES OUTSTANDING
113.4M
|
|
|
MNKD Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
FirstAlert(tm) NYSE-NASDAQ-AMEX Money Index Synopsis
Investrend - 03/16/2010 10:25 AM ET
FDA wants more information on Afrezza
AP Digital - 03/15/2010 4:31 PM ET
Key developments for MANNKIND CORP (MNKD)
FDA Requests Additional Information Regarding Afrezza(TM) in Complete Response Letter to MannKind Corp
03/15/2010
MannKind Corp. announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA(TM) (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes mellitus for the control of hyperglycemia. A complete response letter is issued by the FDA's Center for Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in its current form. The complete response letter related to the AFREZZA application requested several items, including information and currently available clinical data that support the clinical utility of AFREZZA and information about the comparability of the commercial version of the MedTone inhaler to the earlier version of this device that was used in pivotal clinical trials. The letter cited no safety concerns, but requested updated safety data related to AFREZZA. The letter also requested changes to the proposed labeling of the cartridges, foil pouches and cartons. The letter did not require any additional pre-marketing clinical studies in order for the FDA to complete its review of the NDA. As recommended by the FDA, MannKind will request an End-of-Review meeting with the agency to discuss its approach for resolving the remaining issues.
MannKind Corp. - Special/M&A Call
03/15/2010
MannKind Corp. - Special/M&A Call
MannKind Corp. Elects James S. Shannon to its Board of Directors
02/24/2010
MannKind Corporation announced that James S. Shannon, MD, MRCP (UK) has joined the company's Board of Directors. Dr. Shannon is a recognized pharmaceutical industry leader with more than 20 years of experience in senior leadership positions, including serving as Head of Global Development at Novartis Pharma AG in Basel, Switzerland. The addition of Dr. Shannon brings the total number of MannKind Board members to nine. Dr. Shannon is currently the President and CEO of Cerimon Pharmaceuticals Inc. Prior to joining Cerimon in December 2008, he held the position of Global Head of Pharma Development for Novartis AG based in Basel, Switzerland. After joining Sandoz in 1994 as Head of Drug Regulatory Affairs, Dr. Shannon held a number of significant positions in Novartis including Head of the Integration Office for R&D overseeing the creation of the Novartis R&D groups from those of Ciba and Sandoz and also Head of the Cardiovascular Strategic Team. Subsequently he was appointed Global Head of Project Management before being appointed Global Head of Clinical Development and Medical Affairs in 1999, a position that he held until 2005 when he was appointed to Head Pharma Development. He first entered the pharmaceutical industry in 1987 joining Sterling Winthrop working initially in Europe and subsequently in the USA, where he held positions of increasing responsibility in the management of Research and Development ultimately serving as Senior Vice-President, Clinical Development.
MannKind Corporation financial resources
MNKD Competitors
| Company | Last | Change |
| Alkermes Inc | $13.31 USD | -0.02 |
| Dendreon Corp | $36.16 USD | -0.24 |
| Generex Biotechnology Corp | $0.60 USD | -0.0168 |
| Insulet Corp | $15.05 USD | -0.14 |
| Nektar Therapeutics | $15.29 USD | +0.07 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | MNKD | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
MNKD |
||
|
MNKD transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About MannKind Corporation
FDA wants more information on Afrezza
2010-03-19 04:35:32
Quote: Food and Drug Administration has requested more information about the inhaled insulin Afrezza, prompting its shares to plummet.The company said the FDA has completed its review, but needs questions answered before it can approve the company's application.Among other things, the FDA said it wanted clinical data regarding Afrezza and information about the comparability of the commercial version of the MedTone inhaler to the earlier version of the device that was used in pivotal clinical trials.The...Read article
MannKind's Diabetes Device Under More Clouds
2010-03-17 05:05:36
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: (TheStreet) --Common sense went AWOL during MannKind's(MNKD) conference call Tuesday morning.delay approval of Afrezza, the company's inhaled insulin device for diabetes.Yet, the more Mann and his underlings spoke, the more confusing and nonsensical the call became. Doubts and questions about the approvability and commercial viability of MannKind's Afrezza device seem more pronounced today than they were Monday.MannKind's shares closed Monday at $7.89 but rose about 12% in Tuesday's pre-market t...Read article
UPDATE - MannKind fails to make case for Afrezza prospects
2010-03-17 05:05:35
Keywords: Pharmaceuticals (sub-industry),Health and medicine,United States of America,Pharmaceuticals - generic and speciality,Commercial services and supplies (industry group),Industrial machinery,Machinery,Pharmaceuticals - diversified,Denmark,Nordic Countries,Eu
Quote: UPDATE 1-MannKind fails to make case for Afrezza prospects
* MannKind seeks to reassure investors over Afrezza * Remains optimistic the diabetes product will succeed * Investors remain unconvinced; shares fall 2.7 pct By Toni Clarke BOSTON, March 16 (Reuters) - MannKind Corp (MNKD.O) on
Tuesday failed to reassure investors that its experimental
inhaled insulin device will succeed after U.S. regulators
requested more information before agreeing to approve it. MannKind's shares fell 2.7 percent i...Read article
Questioning MannKind's FDA Delay: BioBuzz
2010-03-16 07:44:39
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: FDA Delays MannKind Diabetes Approval(Updated at 10:04 AM EDT)U.S. regulators have delayed the approval of an inhaled insulin drug and device from MannKind Corp.MNKD), the company said Monday.The U.S. Food and Drug Administration asked MannKind to provide updated data on the safety and efficacy of its Afrezza device and additional information about the inhaler used to deliver the insulin to the lungs. The FDA, however, did not ask for new clinical trials, MannKind said in a statement.MannKind sh...Read article
FDA Delays Mannkind Diabetes Approval: BioBuzz
2010-03-16 07:44:39
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: regulators have delayed the approval of an inhaled insulin drug and device from MannKind Corp.(MNKD), the company said Monday.The U.S. Food and Drug Administration asked MannKind to provide updated data on the safety and efficacy of its Afrezza device and additional information about the inhaler used to deliver the insulin to the lungs. The FDA, however, did not ask for new clinical trials, MannKind said in a statement.MannKind shares fell 7% to $9.71 in early Monday trading.complete response le...Read article
FDA wants more information on Afrezza
2010-03-16 07:44:38
Quote: Food and Drug Administration has requested more information about the inhaled insulin Afrezza, prompting its shares to plummet.The company said the FDA has completed its review, but needs questions answered before it can approve the company's application.Among other things, the FDA said it wanted clinical data regarding Afrezza and information about the comparability of the commercial version of the MedTone inhaler to the earlier version of the device that was used in pivotal clinical trials.The...Read article
MannKind Elects James S. Shannon to its Board of Directors
2010-03-01 07:09:44
Quote: Shannon brings the total number of MannKind Boardmembers to nine.“James brings a tremendous wealth of experience to our board ofdirectors,†said Alfred Mann, Chairman and CEO of MannKind. “Hisperspective as an accomplished pharmaceutical executive comes at anexciting time for MannKind Corporation as we prepare to move fromdevelopment to commercialization of our lead product, AFREZZAâ„¢.â€Dr. Shannon is currently the President and CEO of CerimonPharmaceuticals, Inc. Pri...Read article
MannKind Elects James S. Shannon to its Board of Directors
2010-02-26 05:52:39
Quote: Shannon brings the total number of MannKind Boardmembers to nine.“James brings a tremendous wealth of experience to our board ofdirectors,†said Alfred Mann, Chairman and CEO of MannKind. “Hisperspective as an accomplished pharmaceutical executive comes at anexciting time for MannKind Corporation as we prepare to move fromdevelopment to commercialization of our lead product, AFREZZAâ„¢.â€Dr. Shannon is currently the President and CEO of CerimonPharmaceuticals, Inc. Pri...Read article
MannKind loss narrows on lower costs
2010-02-15 02:03:55
Quote: (AP) -- Biotechnology company MannKind Corp. said Monday its fourth-quarter loss narrowed as research and development spending continued to decline.After paying preferred dividends, the company posted a loss of $59.5 million, or 53 cents per share, compared with a loss of $83.3 million, or 82 cents per share, in the prior-year period. It reported no revenue for either quarter.Analysts polled by Thomson Reuters had expected a smaller loss of 40 cents per share.MannKind is developing an inhaled, r...Read article
Earnings roundup: Exxon Mobil, Moog
2010-02-15 02:03:54
Quote: (AP) -- Biotechnology company MannKind Corp. said its fourth-quarter loss narrowed as research and development spending continued to decline.BEDFORD, Mass. (AP) -- Hologic Inc., which makes mammogram systems and other women's health diagnostic tools, said its fiscal first-quarter profit fell 32 percent, hurt by charges and continued capital spending restraint by hospitals.CAMBRIDGE, Mass. (AP) -- E-commerce software maker Art Technology Group Inc. said that improved sales and cost containment he...Read article
MannKind to Present at the 12th Annual BIO CEO & Investor Conference
2010-02-15 02:03:49
Quote: Press ReleaseSource: MannKind CorporationOn Tuesday February 2, 2010, 4:00 pm ESTMannKind Corporation (Nasdaq:- , focused on discovering,developing and commercializing treatments for diabetes and cancer,announced today that it will present at the 12Interested parties can access a link to the live webcast of thepresentations from the News & Events section of the Company's website at MannKind Corporation (Nasdaq:- ) focuses on the discovery,development and commercialization of therapeutic products...Read article
MannKind to Present at the 12th Annual BIO CEO & Investor Conference
2010-02-03 02:09:56
Quote: Press ReleaseSource: MannKind CorporationOn Tuesday February 2, 2010, 4:00 pm ESTMannKind Corporation (Nasdaq:- , focused on discovering,developing and commercializing treatments for diabetes and cancer,announced today that it will present at the 12Interested parties can access a link to the live webcast of thepresentations from the News & Events section of the Company's website at MannKind Corporation (Nasdaq:- ) focuses on the discovery,development and commercialization of therapeutic products...Read article
MannKind Corporation Reports 2009 Fourth Quarter and Full Year Financial Results
2010-02-02 04:24:28
Quote: Currently, theCompany has $185.0 million of available borrowings under the loanagreement with an entity controlled by the Company’s principalstockholder.Pharmaceutical Processing magazine.We also completed much of the technical and clinical bioequivalencystudies necessary for a supplemental NDA for our next-generationinhaler, which we expect to submit to the FDA in the second quarter ofthis year.â€Conference Callhttp://www.mannkindcorp.com.The web site replay will be available for 14...Read article
UPDATE - MannKind says in new partnership talks on Afrezza
2010-02-02 04:24:27
Keywords: Pharmaceuticals (sub-industry),Healthcare services,Health and medicine,Commercial services and supplies (industry group),Industrial machinery,Machinery,United States of America,Denmark,Nordic Countries,Europe,Regulation and enforcement,Corporate Results F
Quote: UPDATE 1-MannKind says in new partnership talks on Afrezza
* Says opened talks with a few new parties * Says reengaged in talks with a previous candidate * Says has enough cash to last till at least Q1 2011 Feb 1 (Reuters) - MannKind Corp (MNKD.O) said it has opened
partnership talks with "a few new parties" on its inhaled
insulin product Afrezza and reengaged in talks with a previous
candidate. In a conference call with analysts, the company also said
it currently has enough cash to fund operat...Read article
MannKind loss narrows on lower costs
2010-02-02 04:24:27
Quote: (AP) -- Biotechnology company MannKind Corp. said Monday its fourth-quarter loss narrowed as research and development spending continued to decline.After paying preferred dividends, the company posted a loss of $59.5 million, or 53 cents per share, compared with a loss of $83.3 million, or 82 cents per share, in the prior-year period. It reported no revenue for either quarter.Analysts polled by Thomson Reuters had expected a smaller loss of 40 cents per share.MannKind is developing an inhaled, r...Read article
MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
2010-02-02 04:24:27
Quote: Item 2.02Results of Operations and Financial Condition
On February 1, 2010, MannKind Corporation issued a press release announcing its
financial results for the fourth quarter and full year 2009. A copy of the press
release is attached as Exhibit 99.1 to this Current Report and is incorporated
herein by reference.
The information in this Current Report is being furnished and shall not be
deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act
of 1934, as amend...Read article
MannKind Corporation Q4 2009 Earnings Call Transcript
2010-02-02 04:24:25
Quote: MannKind Corporation (MNKD)
Q4 2009 Earnings Call Transcript
February 1, 2010 5:00 pm ET
Executives
Matthew Pfeffer – Corporate VP and CFO
Hakan Edstrom – President and COO
Peter Richardson – Corporate VP and Chief Scientific Officer
Alfred Mann – Chairman and CEO
Analysts
Simos Simeonidis – Rodman & Renshaw
Keith Markey – Griffin Securities
Doug Dieter – Imperial Capital
Leah Hartman – CRT Capital
Tom Russo – Baird
Michael Tong ...Read article
MannKind Corporation to Hold 2009 Fourth Quarter and Full Year Financial Results Conference Call on February 1, 2010
2010-01-26 04:32:02
Quote: Presenting from theCompany will be its Chairman and Chief Executive Officer, Alfred Mann;President and Chief Operating Officer, Hakan Edstrom; Corporate VicePresident and Chief Financial Officer, Matthew Pfeffer and CorporateVice President and Chief Scientific Officer, Peter Richardson.http://www.mannkindcorp.com.A telephone replay of the call will be accessible for approximately 14days following completion of the call by dialing (866) 494-3185 or (203)369-1752. A replay will also be available o...Read article
MannKind Earnings Call scheduled for Mon, Feb 1
2010-01-26 04:32:01
Quote: Call DetailsMannKind Earnings Conference Call (Q4 2009)Scheduled
to start Mon, Feb 1, 2010, 5:00 pm EasternAfter
the event has finished, the audio will be availablefrom
this page until Wed, Feb 2, 2011About MannKindMNKD)MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. Its lead product candidate, AFRESA, a rapid-acting insulin that has completed phase 3 clinical trials...Read article
Would you like to leave a comment about MannKind Corporation MNKD
Find out what social network information about MannKind Corporation are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides MannKind Corporation's Stock there is more great penny stock and market information at Realpennies